INJ Search

CLOSE


Int Neurourol J > Volume 30(3); 2026 > Article
Kim: The Afferent Threshold Hypothesis: A Unified Neural Framework for Functional Bladder Capacity and Nocturia

ABSTRACT

The Weiss nocturia indices have structured clinical thinking about nocturia for over 2 decades. By deriving simple ratios from the frequency-volume chart, they classify nocturia into nocturnal polyuria, reduced nocturnal bladder capacity, and mixed etiology. The arithmetic is sound. But the framework rests on an unexamined assumption: that the maximum voided volume, almost always the first morning void, represents “bladder capacity,” and that the gap between this value and daytime voided volumes reflects normal physiology. We propose that what the frequency-volume chart measures during wakefulness is not capacity but a personal adaptive afferent threshold—a neurally determined set-point at which the individual initiates voiding, always below the structural capacity the detrusor permits. The first morning void approximates true structural capacity, revealed when sleep suppresses the cortical circuits that enforce the waking threshold. This reframing unifies the entire overactive bladder spectrum—normal voiding, frequency, urgency, urge incontinence—as positions on a single threshold continuum. It reveals nocturia from “reduced nocturnal bladder capacity” as the intrusion of the waking threshold into sleep when central afferent gating fails. The Weiss parameters captured the output of this system with numerical precision but encoded the threshold artifact as the reference norm, directing a generation of research toward the bladder in patients whose problem may be the brain.

INTRODUCTION: THE TYRANNY OF THE AVAILABLE PARAMETER

Clinical medicine has a recurring problem. When a numerical parameter can be derived from data already being collected, the field adopts it. Adoption is driven not by biological validation but by arithmetic convenience: the index can be calculated, so it is calculated. Once calculated, it enters guidelines, becomes the dependent variable in trials, and structures the questions investigators think to ask. The index creates the conceptual framework rather than reflecting it. The danger is that such indices may encode assumptions about the underlying biology that have never been tested, and that these assumptions, buried inside a formula, become invisible to the investigators who build on them.
The Weiss nocturia indices are a case in point. Introduced in 1998 and refined over the following decade [1-3], they brought quantitative structure to a field that had none. From the 24-hour frequency-volume chart (FVC), a tool already in routine clinical use, Weiss and colleagues derived a set of ratios that classify nocturia into discrete etiological categories: nocturnal polyuria, reduced nocturnal bladder capacity, and mixed. The nocturia index (Ni) divides nocturnal urine volume by maximum voided volume (MVV), telling the clinician whether nocturnal urine output exceeds what the bladder can hold in a single fill. The nocturnal polyuria index (NPi) quantifies the nocturnal share of total urine production. The nocturnal bladder capacity index (NBCi) measures how far nocturnal voided volumes fall short of MVV [1]. Burton et al. [4] subsequently established an unrounded NBCi cutoff of 1.3 as the threshold above which reduced nocturnal bladder capacity should be investigated. These indices were adopted rapidly—by the International Continence Society, by clinical guidelines, by the research literature that followed [5-7].
The indices work. The arithmetic is clean, reproducible, and derivable from a single voiding diary. But embedded within them sits an assumption that has never been scrutinized: that MVV—almost always the first morning void—represents a biological reference point called “bladder capacity,” and that the consistent gap between this value and daytime voided volumes reflects normal physiological variation. This assumption is not stated. It is not argued for. It is built into the denominator of every Weiss formula. And every study that uses MVV as the reference “capacity” inherits it without examination.
We propose that what the FVC measures as “functional bladder capacity” during wakefulness is not a capacity at all. It is a personal adaptive afferent threshold—a neurally determined set-point at which the individual initiates voiding, always below the structural capacity the detrusor permits. MVV approximates true structural capacity, revealed when sleep suppresses the neural circuits that enforce the waking threshold. The gap between MVV and daytime voided volumes is not “normal diurnal variation in bladder capacity.” It is the distance between what the bladder can hold and what the brain will tolerate.
This reframing has consequences that extend beyond nocturia indexing. It unifies the entire overactive bladder (OAB) spectrum—normal voiding, frequency, urgency, urge incontinence— as positions on a single threshold continuum. And it reveals nocturia from “reduced nocturnal bladder capacity” as the intrusion of the waking threshold into sleep when central afferent gating fails. The Weiss parameters captured the output of this system with numerical precision. But by encoding the threshold artifact as the reference norm, they created a framework in which the neural mechanism is invisible and in which a generation of research has been asking the wrong question about a substantial fraction of nocturia patients.

STRUCTURAL CAPACITY VERSUS FUNCTIONAL THRESHOLD: SEPARATING THE BLADDER FROM THE BRAIN

The Bladder as Container

The detrusor is a viscoelastic structure. Its capacity—the maximum volume it can accommodate at low intravesical pressure before passive wall tension rises steeply—is a mechanical property of its wall. This structural capacity does not shrink during the day and expand at night. The collagen-to-smooth-muscle ratio does not shift with the sleep-wake cycle.
We should note that compliance itself may not be entirely independent of neural state. Smith et al. [8] demonstrated in a murine model that bladder compliance decreased when the micturition reflex was abolished under isoflurane, suggesting a degree of central modulation of the detrusor’s mechanical behavior during filling. This finding does not undermine our thesis; it strengthens it by demonstrating that even what we measure as “mechanical” bladder properties are partly neurally determined. What it does mean is that the separation between structure and neural function is less clean than textbook models imply, and that the brain’s influence over the bladder extends deeper than the afferent arm alone.
We can measure structural capacity. Under general or spinal anesthesia, when supraspinal processing of the bladder is suppressed, cystometric capacity reflects what the detrusor permits when the brain is largely removed from the equation. In a primate model, Ghoniem et al. [9] demonstrated that cystometric capacity under flurane anesthesia was roughly 3 times the mean awake voided volume, and comparable to the largest single voided volume recorded in the awake state. More recently, Kim et al. [10] compared maximum anesthetic bladder capacity (MABC), measured under spinal or general anesthesia during surgery, with both MVV from 3-day FVCs and awake maximum cystometric capacity (MCC) in men with lower urinary tract symptoms. MABC correlated significantly with MVV (r=0.41, P<0.001) but showed only a weak correlation with awake MCC (r=0.19, P=0.02). There was no significant difference between MABC and MVV values, whereas a significant discrepancy existed between MABC and MCC in patients with involuntary detrusor contractions. The authors concluded that MABC reflects true bladder capacity by minimizing neural influence, and that MVV approximates this value more faithfully than awake urodynamics. We agree and take it further: MVV approximates structural capacity because sleep, like anesthesia, suppresses the neural circuits that impose the waking voiding threshold.

The Voiding Diary Does Not Measure Capacity

Every daytime void occurs below structural capacity. The individual is not voiding because the bladder is full in any mechanical sense. The individual is voiding because an ascending afferent signal—processed through sacral spinal circuits, relayed through the periaqueductal gray (PAG) to thalamus and cortex— has crossed a subjective threshold at which the desire to void becomes sufficient to initiate the behavior.
This threshold is personal. It is not anatomically fixed. It is shaped by habitual voiding patterns (the “just in case” voider who progressively trains a lower threshold over years), by attentional state (people void less frequently when deeply focused on a task and more frequently when bored or anxious), by cortical interoceptive sensitivity (individual variation in insular cortex processing of visceral afferents), and by learned experience. The evidence that the threshold is modifiable is decisive: bladder retraining programs progressively increase functional voided volumes in patients with OAB, often substantially, without any change in detrusor properties [11, 12]. The bladder has not grown. The threshold has moved.
The International Continence Society (ICS) term “functional bladder capacity” conceals this distinction. It sounds like a property of the container. It is predominantly a property of the nervous system. MVV on the FVC is used as the denominator in every Weiss index. The entire parametric framework rests on MVV as the reference “capacity.” But MVV itself is a product of sleep-state neural suppression, meaning the reference value is already a neural variable. The field has been measuring the brain’s relationship with the bladder and calling it “bladder capacity.”

THE AFFERENT THRESHOLD CONTINUUM: FROM NORMAL VOIDING TO URGE INCONTINENCE

Two Parameters, One Variable

If daytime voided volume is set by a neural threshold rather than by detrusor capacity, then individual variation in voiding patterns reflects individual variation in threshold position, not individual variation in bladder size. The woman who voids every 2 hours at 150 mL and the woman who voids every 5 hours at 400 mL may have identical detrusors. What differs is where their threshold sits.
We propose that the threshold has 2 relevant parameters. The first is position—the afferent signal magnitude (or, in practical terms, the bladder volume) at which the individual initiates or desires voiding. High position means large voided volumes and infrequent voids. Low position means small voided volumes and frequent voids. The second is stability—how consistent the threshold is across filling cycles. A stable threshold produces a predictable voiding pattern. An unstable threshold produces unpredictable urgency episodes interspersed with voids at variable volumes.
These 2 parameters generate the clinical phenotypes we currently classify as separate diagnostic entities. A high, stable threshold is normal infrequent voiding. A moderate, stable threshold is normal average voiding. A low, stable threshold is the frequent voider whom we reassure as having a “small bladder.” A low, unstable threshold is OAB with urgency. And a threshold that has collapsed to or below the level of the reflex voiding trigger is OAB with urge incontinence. These are not 5 diseases. They are 5 positions on a single continuum.

What Moves the Threshold

The threshold position is determined by the interaction of factors at every level of the neural axis. Peripheral factors set the gain of the afferent signal per unit of bladder volume: urothelial receptor sensitivity, afferent nerve density, suburothelial interstitial cell signaling, detrusor tone, and the presence or absence of involuntary microcontractions all determine how loud the signal is for a given volume. Spinal factors modulate the signal at the segmental level: interneuron excitability at S2– S4, and descending facilitation or inhibition from brainstem nuclei, determine how much of the peripheral signal reaches supraspinal centers. Supraspinal factors set the central gain: the PAG set-point, thalamic relay efficiency, insular interoceptive processing sensitivity, and prefrontal executive override all determine how the brain responds to the arriving signal [13-16]. And adaptive factors recalibrate the system over time: chronic habitual patterns shift the threshold in the direction of reinforcement.
The clinical implication is that “OAB” is not one disease with one mechanism. It is any condition that shifts the threshold leftward. Detrusor overactivity and urothelial sensitization do so from below, by increasing the gain or lowering the activation point of the peripheral afferent signal. Increased cortical interoceptive processing does so from above, amplifying the central response to a normal signal. Impaired prefrontal suppression does so by weakening the executive brake on the voiding reflex entirely. The same clinical syndrome—urgency, frequency, incontinence— emerges from mechanistically distinct origins.

Urgency Reconsidered

The ICS defines urgency as “the sudden compelling desire to pass urine, which is difficult to defer” [5]. This is a description of a sensory experience. The conventional OAB model privileges a motor explanation: involuntary detrusor contractions produce urgency, and urgency is therefore the conscious awareness of a bladder event. But urgency occurs in patients without demonstrable detrusor overactivity on urodynamics—so-called sensory urgency, which in some series accounts for half or more of OAB presentations [17].
The threshold model resolves this without requiring 2 separate pathologies. In motor OAB, involuntary contractions produce steep afferent signals that cross the threshold from below. In sensory OAB, the threshold itself has dropped from above: the cortical gain is set too high. The patient is processing a normal peripheral signal with excessive central amplification. Functional brain imaging supports this. Griffiths and colleagues demonstrated that patients with OAB show increased activation of the insula and anterior cingulate cortex during bladder filling compared with controls [18-20]. Subsequent work found that in patients with urgency urinary incontinence, these interoceptive network regions show activation patterns resembling those described in other visceral “hypervigilant” states such as irritable bowel syndrome [21]. Whether increased insular activation is the cause or the consequence of urgency cannot be determined from cross-sectional imaging data alone, but the pattern is what the threshold model predicts: a central gain problem rather than a purely peripheral motor event.

Urge Incontinence as Threshold Collapse

Continence requires that the interval between crossing the urgency threshold (conscious awareness of the need to void) and crossing the reflex voiding threshold (PAG/pontine micturition center [PMC] activation of the detrusor contraction) is long enough for voluntary inhibition to engage. Urge incontinence occurs when this interval collapses to zero—when the afferent signal crosses both thresholds simultaneously, or when the 2 thresholds have converged so closely that no window for voluntary control remains.
Two routes lead to this collapse. The peripheral route: detrusor overactivity produces signal transients steep enough to breach both thresholds at once. The central route: prefrontal inhibitory capacity has weakened with age, neurodegeneration, or cognitive decline, shrinking the voluntary suppression window. This framework is consistent with the clinical observation that urge incontinence prevalence increases with both bladder pathology and with age-related cognitive and brain changes [20]. Both mechanisms narrow the same gap from different directions. The elderly patient with urgency during the day and nocturia at night is not carrying 2 diagnoses. She has a single threshold positioned low on the continuum, with the additional burden of progressively failing nocturnal gating that allows that threshold to persist into sleep.

SLEEP AS THE NATURAL EXPERIMENT: HOW NEURAL GATING UNMASKS STRUCTURAL CAPACITY

The Nightly Proof

Sleep is not a tangential phenomenon in this model. It is the proof of concept. Every night, in every healthy individual, the cortical contribution to the afferent threshold is withdrawn— thalamic gating suppresses ascending sensory relay, insular interoceptive processing falls silent, and the prefrontal executive that normally modulates voiding decisions goes offline. What remains is the bladder filling against structural constraint, and nothing else. The first morning void is the result: a volume that approximates structural capacity because the neural surveillance that normally triggers voiding before structural capacity is reached has been suspended for 7 or 8 hours.
This is why MVV is almost always the first morning void. In a multicenter Korean study of 177 healthy children, daytime maximum voided volume (MVVDT) was significantly less than MVV (179.5±71.1 mL vs. 227.0±79.2 mL), and the mean MVVDT/MVV ratio was 0.80 [22]. The first morning void was the MVV in more than 70% of cases [23, 24]. In adults, the pattern is the same. The 20%–25% increment from daytime maximum to first morning void is the neural threshold contribution, made visible by its removal during sleep.

Three Levels of Suppression

The afferent threshold is a product of cortical processing. Sleep suppresses that processing at every relevant level of the neural axis, and the mechanisms are well characterized.
At the thalamic level, the reticular thalamic nucleus (TRN) functions as the gate for ascending sensory information [25, 26]. During nonrapid eye movement (NREM) sleep, thalamocortical neurons shift from tonic to burst-pause firing mode, driven by low-threshold Ca2+ spikes dependent on T-type channels [27]. This mode change fragments the continuous ascending sensory stream into periodic bursts punctuated by silence—the cellular basis of sleep spindles and delta waves. The TRN is parcellated by sensory modality, and visceral afferents relayed through the posterior and medial thalamic nuclei are subject to the same gating [25]. Lewis et al. [28] demonstrated that optogenetic activation of TRN is sufficient to induce local NREMlike slow waves and reduce behavioral arousal, confirming TRN as a causal mechanism for sensory gating during sleep.
At the cortical level, the insular cortex—the primary cortical target for visceral interoception [15]—is profoundly deactivated during NREM sleep. The conscious awareness of bladder filling that drives the social and behavioral decision to void is effectively eliminated.
At the executive level, the medial prefrontal cortex (mPFC) provides the descending “permission” signal to PAG that, when combined with ascending bladder afferent input, determines whether the voiding reflex is activated [13, 14, 29]. During NREM, mPFC is among the most deactivated cortical regions. The PAG summation model, well described in the neurourology literature [29], requires that mPFC input and bladder afferent input together exceed a set-point for voiding to be triggered. During sleep, the mPFC contribution is effectively zeroed. The voiding threshold rises to be determined by peripheral signal alone—and that peripheral signal does not reach sufficient intensity until the bladder approaches structural capacity.
The net effect of these 3 converging mechanisms—thalamic gating of ascending afferents, loss of insular interoceptive representation, and withdrawal of mPFC input to PAG—is that the personal adaptive threshold is suspended. The bladder fills until mechanical stretch alone becomes sufficient to trigger arousal and voiding. MVV is not “increased nocturnal capacity.” It is unmasked structural capacity—the volume the detrusor holds when the brain stops triggering voiding prematurely.

The Evolutionary Nonargument

There is no obvious adaptive reason for a smaller daytime bladder capacity. Other visceral organs do not show a comparable waking-to-sleeping volume differential that is then treated as a fundamental capacity parameter. The bladder’s day-night volume gap exists because it is the only visceral organ under continuous cortical interoceptive surveillance with a behaviorally triggered emptying reflex. The gap is a byproduct of that neural architecture, not an independent physiological program.
The circadian bladder literature has identified clock gene expression and connexin 43 oscillation in detrusor tissue, and these findings have been interpreted as evidence for an autonomous circadian bladder capacity program [30]. We suggest a simpler reading. Muscles adapt their gene expression to cyclic loading patterns. The detrusor, subjected nightly to a stretchand-empty cycle imposed by the neural day-night voiding difference, expresses genes consistent with that mechanical rhythm. The circadian gene expression is downstream of the neural phenomenon, not its cause.

NOCTURIA RECONSIDERED: THE INTRUSION OF THE WAKING THRESHOLD INTO SLEEP

What “Reduced Nocturnal Bladder Capacity” Actually Is

The threshold model reframes nocturia from “reduced nocturnal bladder capacity” in a specific and clinically consequential way. When the Weiss parameters identify NBCi >1.3, they detect that the patient voids during sleep at volumes below MVV. The conventional interpretation directs the clinician toward the bladder: something about the detrusor is limiting nocturnal accommodation. The threshold interpretation says: the waking afferent threshold—wherever it sits on the continuum—has persisted into sleep because central gating has failed to reset it upward toward structural capacity.
The distinction matters because it determines treatment targets. A true detrusor limitation (fibrosis, radiation damage, severe uninhibited contractions) requires treatment directed at the bladder. A gating failure requires treatment directed at sleep quality, central neural processing, or both. The same NBCi value carries a different mechanistic meaning and demands a different therapeutic approach.

Why the Waking Threshold Intrudes

The most common reason for nocturnal gating failure is the simplest: age-related deterioration of NREM sleep. Slow-wave sleep percentage declines progressively with age. TRN-mediated sensory gating weakens. The cortical suppression that normally suspends the afferent threshold becomes incomplete [31]. The threshold no longer resets fully, and the patient begins to void during sleep at volumes closer to their daytime voided volumes than to structural capacity.
This predicts that nocturia prevalence should track age-related sleep quality decline. It does. It also predicts that any cause of sleep fragmentation—obstructive sleep apnea, periodic limb movements, chronic pain, environmental noise—should partially reinstate the waking threshold by periodically restoring waking-type cortical processing. This offers a complementary explanation for a well-established clinical observation: continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea reduces nocturia [32]. While hemodynamic mechanisms have been emphasized—reduced atrial distension, reduced atrial natriuretic peptide release, reduced nocturnal diuresis— the restoration of consolidated NREM sleep may also contribute by restoring afferent gating and allowing the bladder to reach higher volumes before triggering a void. Both mechanisms are likely operative; the threshold model adds a neural dimension to what has been treated as a purely hemodynamic phenomenon.

The OAB-Nocturia Link

The threshold model explains why OAB and nocturia so frequently coexist. An OAB patient, by definition in this model, has a waking threshold positioned low on the continuum. A lower waking threshold requires more gating to reset fully during sleep. The same degree of age-related NREM deterioration that leaves a normal-threshold individual continent at night may be insufficient for the OAB patient, because the distance the gating must cover—from a low waking threshold up to structural capacity—is greater.
This is consistent with published data on age-related shifts in nocturia pathogenesis. Weiss et al. [3] found that in younger OAB patients, nocturia is predominantly associated with elevated NBCi, while in older patients it shifts toward elevated NPi. The threshold model offers an additional interpretive dimension. In younger patients, the waking threshold is low (OAB phenotype) and sleep gating still partially compensates, but not fully, producing nocturia at substructural volumes. In older patients, gating itself deteriorates while renal hemodynamic changes simultaneously increase nocturnal urine production. The 2 axes compound. This is why mixed etiology is so common in the elderly—it reflects the convergence of rising production and failing gating on a threshold that may also be drifting downward with age [7].

THE DEAD WEIGHT: RETURNING TO THE WEISS PARAMETERS

Having established the threshold model, we return to where we began. The Weiss indices are not wrong. Their arithmetic is correct. Their clinical contribution was genuine: before Weiss, the nocturia field had no quantitative language at all. The indices gave clinicians a way to parse the FVC into actionable categories, and this was a real advance.
But the framework carries assumptions that the threshold model exposes, and those assumptions have shaped a generation of research in ways that are not benign.

What the Parameters Capture Correctly

The NPi remains fully valid. Nocturnal polyuria is a renal and hemodynamic phenomenon—excessive urine production during sleep, driven by fluid redistribution, hormonal shifts, or renal concentrating defects [6, 7]. The threshold model does not touch urine production. NPi measures it correctly. The Ni is likewise sound as a descriptive index: the number of nocturnal voids exceeding what MVV would predict is a clinically useful number regardless of the mechanism driving it. The FVC itself is not in question.

What the NBCi Obscures

The problem is specific to NBCi and to its interpretation. NBCi uses MVV as the reference “capacity.” We have argued that MVV is not capacity in any mechanical sense; it is the absence of the neural threshold. The denominator is a neural product. The cutoff of 1.3 encodes the “normal” distance between the waking threshold and structural capacity as expected variation. When NBCi exceeds 1.3, the conventional interpretation— “reduced nocturnal bladder capacity”—directs the clinician toward the bladder.
But at least 4 distinct mechanisms can produce an identical NBCi elevation. Genuine detrusor dysfunction—a fibrotic, irradiated, or chronically inflamed bladder—truly cannot accommodate normal volumes; this is the mechanism the conventional interpretation assumes. Peripheral afferent sensitization, as in interstitial cystitis, produces abnormally steep afferent signals from an intact detrusor, signals steep enough to breach even sleep-state gating. Central gating failure allows the waking threshold to persist into sleep because NREM quality is impaired, with a structurally and functionally normal bladder underneath. And a waking threshold already positioned so low—severe OAB—may simply exceed the distance that even intact gating can cover. The NBCi is the same number in all 4 cases. The treatment is different in each.

The Weight of Accumulated Assumption

Every study that stratifies patients by NBCi inherits the assumption that elevated NBCi means a bladder problem. Trials of antimuscarinics for nocturia have been designed around this assumption. Etiological classifications that divide nocturia into “production” and “capacity” arms encode it. The accumulated literature becomes self-reinforcing: the parameter defines the question, the question generates data interpreted through the parameter, and the data are cited as evidence that the parameter captures the biology. This is what we mean by dead weight. It is not malice or incompetence. It is the natural history of a convenient index that was adopted before its biological assumptions were tested, and that became progressively harder to question as the literature built on it grew.

THERAPEUTIC IMPLICATIONS: MATCHING TREATMENT TO MECHANISM

The threshold model does not merely reclassify patients. It redirects treatment.

Antimuscarinics and Beta-3 Agonists

Antimuscarinic agents have documented efficacy in reducing nocturia in OAB patients, and the effect is more pronounced in patients with elevated NBCi [33]. The conventional explanation is that these drugs reduce detrusor overactivity and thereby increase nocturnal bladder capacity. The threshold model offers a complementary reading. Antimuscarinics block muscarinic receptors not only on detrusor smooth muscle but also on urothelial cells and suburothelial afferent nerve terminals, thereby reducing the gain of the peripheral afferent signal [34]. In threshold terms, they shift the signal rightward, effectively raising the threshold from below. This explains why they partially help nocturia even in patients without detrusor overactivity on urodynamics: they are modulating the afferent input to the threshold, not correcting a motor defect. The same logic applies to beta-3 agonists, where emerging evidence suggests afferent effects alongside the canonical detrusor relaxation [35].

Sleep as a Primary Treatment Target

If nocturia in the gating-failure phenotype results from impaired NREM allowing the waking threshold to persist into sleep, the logical treatment target is sleep quality. The evidence is already there, scattered across the sleep medicine and urology literatures without a unifying framework. CPAP for obstructive sleep apnea reliably reduces nocturia [32]. Cognitive behavioral therapy for insomnia (CBT-I) improves sleep consolidation and NREM architecture. The threshold model predicts that CBT-I should reduce nocturia in patients with elevated NBCi and normal urodynamics—a hypothesis that, to our knowledge, has not been the subject of a dedicated trial but that the model renders directly testable.

Bladder Retraining Reframed

Bladder retraining works because it moves the waking threshold rightward: the patient learns to tolerate higher volumes before initiating a void [11]. This is not “increasing bladder capacity.” It is recalibrating a neural set-point. The threshold model predicts that effective bladder retraining should reduce both daytime urgency and nocturia, because raising the waking threshold reduces the gating demand during sleep. Existing outcome data are consistent with this prediction [12].

Neuromodulation Positioned

Sacral neuromodulation and posterior tibial nerve stimulation modulate afferent processing at spinal and supraspinal levels [36]. In the threshold model, these therapies recalibrate the afferent gain centrally, raising the threshold. This explains their efficacy across the entire OAB spectrum—urgency, frequency, urge incontinence, and nocturia—without altering detrusor properties. Functional imaging evidence supports this interpretation: sacral nerve stimulation in OAB responders decreases activation in insular, cingulate, and prefrontal cortices, and deactivates the PAG [37, 38]. It is acting on the threshold circuitry.

WHY THE THRESHOLD ONLY FALLS: THE RATCHET MECHANISM

The threshold model as presented so far explains what functional bladder capacity is (a neural set-point), where the clinical phenotypes sit on the continuum (normal through urge incontinence), and how sleep unmasks structural capacity (by suspending the set-point). What it has not yet explained is the directionality of change. Why does functional voided volume tend to decrease across the lifespan? Why does the “small bladder” get smaller? The answer lies in a fundamental asymmetry built into the act of voiding itself.

Voiding as a Self-reinforcing Act Without Corrective Feedback

Consider what happens when a person voids. The bladder is a hidden organ. Unlike the skin, the joints, or even the gut (whose fullness can be inferred from a meal), the bladder provides no objective external signal of its fill state. The individual cannot see the volume inside. The only information available is the subjective sense of fullness—an interoceptive signal processed through the very cortical circuits we have been discussing. When that signal crosses the threshold, the person voids. Upon voiding, immediate relief follows. The act is rewarded.
This is the critical asymmetry. There is positive reinforcement for voiding at the moment the threshold is crossed, but there is no negative feedback for voiding prematurely. The person who voids at 200 mL when the bladder could have held 400 mL receives the same relief as the person who waits. Nobody tells you that you voided too soon. There is no signal, no discomfort, no visible indicator, no physiological penalty that says “you could have held more.” The feedback is one-directional: voiding feels good, therefore void.
This creates a ratchet. Every voiding event reinforces the current threshold or nudges it lower, because the reward of relief is registered at whatever volume triggered it. If a person happens to void at a slightly lower volume on one occasion—because of convenience, habit, or mild urgency—and experiences the same relief, that lower volume becomes part of the reinforced range. Over months and years, the threshold drifts downward. It cannot drift upward through the same mechanism, because there is no spontaneous reward for holding longer. The ratchet has no pawl release.
This is why bladder retraining works and why it requires deliberate effort against the natural grain of the system. Retraining imposes an artificial corrective signal—the clinician or the protocol tells the patient to wait, to tolerate, to override the threshold. Without that external intervention, the system has no self-correcting mechanism. It is, in engineering terms, an open-loop controller with a positive-feedback bias. It will drift toward lower thresholds given enough time. The clinical evidence supports this interpretation: bladder retraining programs consistently increase functional voided volumes by 50% or more without any demonstrable change in detrusor properties [11, 12], and clinical experience confirms that gains erode when patients revert to habitual voiding patterns after treatment ends. The intervention moves the threshold; the biology does not move it back.
The analogy to other interoceptive behaviors is instructive. Scratching an itch provides immediate relief and reinforces scratching at lower itch thresholds; chronic scratching lowers the itch threshold (the itch-scratch cycle is well documented in dermatology). Eating at the first mild sensation of hunger provides immediate reward and, over time, trains earlier eating; the result is habitual snacking in people who are not calorically depleted. In each case, the behavior that responds to a subjective interoceptive signal is rewarded immediately and has no builtin penalty for premature activation. The bladder is no different. Voiding is scratching is eating: the body rewards the response without evaluating whether the response was necessary.

Anxiety as the Force That Turns the Ratchet

If the positive-feedback asymmetry is the mechanism of the ratchet, anxiety is the force that turns it. The relationship between anxiety and OAB is not speculative; it is one of the most consistently demonstrated associations in the lower urinary tract symptoms literature. A Norwegian 10-year longitudinal study found that the relationship is bidirectional: the presence of anxiety at baseline increased the odds of developing urgency incontinence, and urgency incontinence at baseline increased the odds of developing anxiety [39]. Daily symptom tracking in women with OAB confirms that same-day urgency scores are positively associated with same-day anxiety, depression, and stress ratings [40]. The association is biologically grounded. In a Japanese community-based cross-sectional study, serum serotonin levels were inversely correlated with OAB symptom scores, and low serum serotonin was independently associated with the presence of OAB on multivariable analysis [41]. In animal models, activation of raphe serotonergic neurons or spinal serotonin receptors inhibits reflex bladder contractions and suppresses firing of spinal dorsal horn neurons receiving pelvic afferent input [42]. Duloxetine, a serotonin-norepinephrine reuptake inhibitor, increases urethral sphincter activity and decreases bladder activity through central mechanisms—a pharmacological proof that serotonergic modulation can shift the voiding threshold [42]. In rodent stress models, chronic psychological stress produces bladder overactivity with enhanced afferent nerve activity [43]. And in women with OAB and comorbid anxiety, quantitative sensory testing reveals elevated temporal summation of pain—an objective marker of central sensitization to C-fiber input—supporting the hypothesis that anxiety amplifies visceral afferent processing centrally rather than peripherally [44].
The threshold model integrates these findings into a single narrative. In states of heightened anxiety, central serotonin dynamics shift toward reduced inhibition of the micturition reflex and increased sensitivity across visceral sensory channels. The anxious individual does not selectively become more aware of the bladder; the entire interoceptive gain increases. Bladder filling— normally a background signal processed below the level of conscious attention at moderate volumes—becomes salient at lower volumes than it would be in a relaxed state.
An acute anxiety episode pushes the threshold downward transiently. The person voids at a lower volume, experiences relief (both from the bladder and from the anxiety-driven urgency), and the ratchet registers the event. When the anxiety resolves, the threshold does not necessarily return to its prior position, because the positive-feedback mechanism has now reinforced voiding at the lower volume. Repeated anxiety episodes across a lifetime mean repeated downward ratcheting. The threshold drifts lower with each cycle that is not actively corrected.
This offers a mechanistic account for several observations that the conventional OAB model handles poorly. The wellknown association between anxiety disorders and OAB is not a comorbidity in the conventional sense but a direct causal pathway in which anxiety drives the threshold downward through serotonergic amplification of visceral afferents. The female preponderance of OAB takes on new meaning: women report higher rates of anxiety disorders across the lifespan, and the ratchet model predicts that higher cumulative anxiety exposure translates to greater lifetime threshold decline. The progressive nature of “small bladder” complaints becomes explicable: the patient who has voided frequently for decades has had decades of positive-feedback reinforcement at low volumes, compounded by whatever anxiety-driven downward shifts occurred along the way. The “small bladder” is not an anatomical finding. It is the accumulated result of a lifetime of unreflective voiding in a system that only rewards emptying and never rewards waiting.

The Pathological Consequence: When the Threshold Falls Below the Voiding Reflex

The first 2 mechanisms explain why the threshold drifts downward. This third mechanism explains why that drift is not merely suboptimal but actively harmful to the lower urinary tract.
Normal micturition is an autonomic event. At physiological volumes, the ascending afferent signal reaches sufficient intensity to activate the spinobulbospinal voiding reflex through the PAG and PMC. The detrusor contracts. The urethra relaxes. The 2 events are coordinated, and voiding proceeds at low urethral pressures with complete emptying [13]. This is the reflex for which the system was designed: it requires a certain afferent signal magnitude to trigger, and that magnitude corresponds to a volume near the structural capacity of the bladder.
When the afferent threshold has ratcheted well below the reflex voiding volume, a mismatch emerges. The patient perceives urgency at, for example, 150 mL—the subjective threshold has been crossed. The patient goes to the toilet expecting to void. But the bladder is not full enough to trigger the normal voiding reflex. The detrusor does not contract on its own. The urethra does not relax coordinately. The patient experiences what clinicians recognize as hesitancy: the void does not come when expected.
What happens next is the pathological step. Rather than waiting for the bladder to fill further and the reflex to engage naturally, the patient strains. Abdominal pressure is elevated to force urine through an outlet that has not received the parasympathetic signal to relax. The consequences of this pattern are well characterized in the dysfunctional voiding literature, though they have not previously been linked to the threshold ratchet. Voiding against a nonrelaxed sphincter produces elevated voiding detrusor pressures, detrusor hypertrophy, and dilatation of the proximal urethra—the “spinning top” deformity visible on voiding cystourethrography [45, 46]. In pediatric populations, dysfunctional voiding carries the highest rates of urinary tract infection, urinary incontinence, and vesicoureteral reflux of any functional lower urinary tract disorder [45]. In adult women, Valsalva voiding is recognized as a common compensatory pattern that, after incontinence surgery restoring normal urethral pressure transmission, can produce voiding failure—demonstrating that these patients were never voiding by reflex but by strain [47]. The internal urethral sphincter is subjected to shear forces it was not designed to accommodate during voiding. The prostatic urethra, in men, is compressed between elevated intravesical pressure from above and a sphincter that has not fully relaxed below.
There is a principle in medicine so well established that it hardly requires stating: chronically elevated pressure in a physiological compartment is pathogenic. Systemic hypertension damages the vasculature and end organs. Elevated intracranial pressure destroys neural tissue. Elevated intraocular pressure causes glaucoma. Elevated intra-abdominal pressure produces compartment syndrome. In every case, the mechanism is the same:sustained pressure exceeding the design tolerance of the tissue causes progressive structural damage. We accept this without controversy for the cardiovascular system, the central nervous system, the eye, and the abdomen. It would be remarkable if the urethra were the sole exception—if chronic elevation of voiding pressures through habitual straining against a nonrelaxed outlet carried no consequence for the tissues subjected to that pressure. The dysfunctional voiding literature in children demonstrates that it does: elevated voiding pressures produce detrusor hypertrophy, vesicoureteral reflux, and recurrent infection [45, 46]. What has not been asked is whether the same principle applies, at lower intensity but over far longer duration, to the millions of adults who strain-void habitually because their afferent threshold has ratcheted below the reflex voiding volume.
This is not a rare clinical scenario. It is the daily reality of patients with low voiding thresholds who strain-void habitually without recognizing that their voiding pattern is abnormal. Over years, the consequences accumulate. Chronic elevated urethral pressures during voiding contribute to prostatic inflammation— a mechanical etiology for prostatitis that is distinct from the infectious and autoimmune pathways but that may explain a substantial fraction of chronic pelvic pain in men with concurrent lower urinary tract symptoms. In women, chronic strain voiding against a nonrelaxed sphincter risks progressive damage to the internal urethral sphincter mechanism, paradoxically contributing to the very incontinence that the patient’s frequent voiding was attempting to prevent.
The clinical irony is stark. The patient voids frequently to avoid incontinence. The frequent voiding ratchets the threshold lower. The low threshold produces voiding attempts at subphysiological volumes. The subphysiological voiding requires straining. The straining damages the sphincter. The damaged sphincter produces incontinence. The cycle is self-perpetuating, and at no point does the patient or the clinician identify the root cause as the threshold itself.
The corrective implication is direct. Allowing the bladder to fill to volumes that approximate the physiological maximum— the volume at which the autonomous voiding reflex is triggered naturally—permits coordinated detrusor contraction with urethral relaxation, voiding at low outlet pressures, and complete emptying without straining. This is not “holding it too long.” This is voiding at the volume the system was built to handle. The nocturnal MVV tells us what that volume is. The goal of conscious threshold expansion is to bring daytime voiding volumes closer to that reference, not because larger voids are inherently virtuous, but because the voiding reflex functions correctly only when the bladder is full enough to trigger it.

The Complete Picture and Potential Clinical Consequences

We can now state the full model. Structural bladder capacity is a mechanical property of the detrusor that is relatively stable across the lifespan in the absence of disease. What declines is not capacity but threshold. The threshold declines because voiding is a positively reinforced interoceptive behavior with no built-in corrective for premature activation, and because anxiety-driven serotonergic amplification of visceral afferents provides the episodic force that ratchets the threshold downward. As the threshold falls below the volume required to trigger the normal voiding reflex, the patient begins to strain-void, producing elevated urethral pressures that damage the outlet and perpetuate a cycle of worsening symptoms. Sleep normally resets the threshold upward toward structural capacity by suppressing the cortical circuits that enforce it. Nocturia from “reduced nocturnal bladder capacity” occurs when sleep gating fails to cover the widening gap between a chronically declining waking threshold and a stable structural capacity. The Weiss parameters detect the output of this system without recognizing any part of the mechanism.
But the model raises questions that extend beyond nocturia, and we close with two that the field has not asked because the current framework does not generate them.
The first concerns chronic prostatitis. It is among the most common diagnoses in urology, yet its pathogenesis remains poorly understood. The infectious model explains acute prostatitis well enough, but chronic prostatitis—the form that fills clinics—is overwhelmingly abacterial. If infection is not the cause in most cases, what is? The threshold model suggests an answer. A man who has spent years voiding at sub-reflex volumes is a man who has spent years straining against a urethra that has not received the parasympathetic signal to relax. The prostatic urethra sits between the elevated intravesical pressure generated by abdominal straining and a bladder neck and external sphincter that have not coordinately opened. The mechanical shear stress on the prostatic parenchyma is chronic, repetitive, and unrecognized by either the patient or the clinician, because neither identifies the voiding pattern as abnormal. We do not ask why chronic prostatitis is so prevalent while acute bacterial prostatitis is comparatively rare. Perhaps we should. If the answer is mechanical rather than infectious, then the prevalence of chronic prostatitis is a downstream consequence of the threshold ratchet operating across millions of men over decades, and the treatment is not antibiotics or alphablockers but correction of the voiding pattern itself.
The second concerns stress urinary incontinence in women. The standard etiological narrative centers on childbirth: vaginal delivery damages the pelvic floor, denervates the sphincter, and the cumulative obstetric trauma explains why stress incontinence is so much more common in parous women. Childbirth is undoubtedly a risk factor. But the narrative leaves a question unasked. Stress incontinence is common in nulliparous women as well. It increases with age even in women whose last delivery was decades earlier. And the pelvic floor, like any muscular structure, has regenerative and adaptive capacity—it is not obvious that a single mechanical insult, however severe, should produce progressive incompetence 30 years later without an ongoing mechanism of injury. The threshold model proposes one. A woman who has spent decades voiding at low volumes, straining against a continent outlet that has not reflexively relaxed, has been subjecting her internal urethral sphincter and pelvic floor to repetitive shear forces with every void. The damage is cumulative, subclinical, and entirely invisible on the voiding diary because the diary records only volumes and times, not voiding pressures or straining effort. Childbirth may be the acute insult that initiates vulnerability. But decades of strain voiding from a ratcheted-down threshold may be the chronic mechanism that converts that vulnerability into progressive incontinence. If so, then the prevention of stress incontinence in women begins not with pelvic floor exercises after delivery but with conscious threshold maintenance across the lifespan—a reframing that moves the entire problem from the pelvis to the brain.

CONCLUSION AND PROPOSED DIRECTIONS

Functional bladder capacity is a misnomer. What the voiding diary records during wakefulness is a personal adaptive afferent threshold—a neurally determined set-point that governs when the individual voids, always below the structural capacity the detrusor permits. This threshold drifts downward across the lifespan through a ratchet mechanism: voiding is rewarded immediately and without corrective feedback for premature activation, and anxiety-driven serotonergic amplification provides the recurring force that pushes the threshold lower. When the threshold falls far enough below the physiological reflex volume, the patient begins to strain-void against a nonrelaxed outlet, producing the very urethral damage and sphincteric incompetence that frequent voiding was meant to prevent. Sleep normally suspends this threshold by suppressing thalamocortical afferent processing, revealing structural capacity as the first morning void.
Normal voiding, frequent voiding, urgency, and urge incontinence are not separate diseases. They are positions on a single threshold continuum. Nocturia attributed to “reduced nocturnal bladder capacity” is, in a substantial subset of patients, the intrusion of a chronically lowered waking threshold into sleep because central afferent gating has failed to compensate.
The Weiss parameters measured the consequences of this system with precision and gave the nocturia field a quantitative language it badly needed. But by embedding the threshold artifact into the reference framework as “normal,” they directed clinical thinking toward the bladder in patients whose problem is the brain. The diagnostic framework should evolve to reflect this. We propose that elevated NBCi should trigger a differential diagnosis that includes, alongside genuine detrusor dysfunction, 2 neural categories: central gating failure (impaired NREM sleep allowing threshold intrusion) and thresholdratchet pathology (a chronically lowered waking threshold exceeding the capacity of intact gating to compensate).
These are hypotheses, not conclusions. They require testing. But they are hypotheses that the current parametric framework cannot generate, because that framework begins and ends with the bladder. The threshold model begins with the brain, and from that vantage point, the questions change.
What is observed on the voiding diary is not what should be. The bladder can hold more than we let it.

NOTES

Grant/Fund Support
This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Conflict of Interest
JWK, a member of the Editorial Board of the International Neurourology Journal, is the sole author of this article. However, he had no involvement in the editorial evaluation of this manuscript or in the decision to publish it. Except for this role, no potential conflict of interest relevant to this article was reported.
AUTHOR CONTRIBUTION STATEMENT
All contributions to this paper were made by the sole author(JWK).

REFERENCES

1. Weiss JP, Blaivas JG, Stember DS, Chaikin DC. Evaluation of the etiology of nocturia in men: the nocturia and nocturnal bladder capacity indices. Neurourol Urodyn 1999;18:559-65. PMID: 10529704
crossref pmid
2. Weiss JP, Blaivas JG, Stember DS, Brooks MM. Nocturia in adults: etiology and classification. Neurourol Urodyn 1998;17:467-72. PMID: 9776009
crossref pmid
3. Weiss JP, Blaivas JG, Jones M, Wang JT, Guan Z; 037 Study Group. Age related pathogenesis of nocturia in patients with overactive bladder. J Urol 2007;178:548-51 discussion 551. PMID: 17570424
crossref pmid
4. Burton C, Weiss JP, Parsons M, Blaivas JG, Coats AC. Reference values for the Nocturnal Bladder Capacity Index. Neurourol Urodyn 2011;30:52-7. PMID: 20882675
crossref pmid pdf
5. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78. PMID: 11857671
crossref pmid
6. Weiss JP, Everaert K. Management of nocturia and nocturnal polyuria. Urology 2019;133S:24-33. PMID: 31586470
crossref pmid
7. van Kerrebroeck P, Abrams P, Chaikin D, Donovan J, Fonda D, Jackson S, et al. The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:179-83. PMID: 11857672
crossref pmid
8. Smith PP, Deangelis AM, Kuchel GA. Evidence of central modulation of bladder compliance during filling phase. Neurourol Urodyn 2012;31:30-5. PMID: 22038779
crossref pmid pdf
9. Ghoniem GM, Shoukry MS, Monga M. Effects of anesthesia on urodynamic studies in the primate model. J Urol 1996;156:233-6. PMID: 8648813
crossref pmid
10. Kim MH, Suh J, Kong HJ, Oh SJ. Maximum voided volume is a better clinical parameter for bladder capacity than maximum cystometric capacity in patients with lower urinary tract symptoms/benign prostatic hyperplasia: a prospective cohort study. Int Neurourol J 2022;26:317-24. PMID: 36599340
crossref pmid pmc pdf
11. Wyman JF, Fantl JA, McClish DK, Bump RC. Comparative efficacy of behavioral interventions in the management of female urinary incontinence. Continence Program for Women Research Group. Am J Obstet Gynecol 1998;179:999-1007. PMID: 9790388
pmid
12. Fantl JA, Wyman JF, McClish DK, Harkins SW, Elswick RK, Taylor JR, et al. Efficacy of bladder training in older women with urinary incontinence. JAMA 1991;265:609-13. PMID: 1987410
crossref pmid
13. Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci 2008;9:453-66. PMID: 18490916
crossref pmid pmc pdf
14. Griffiths D, Tadic SD. Bladder control, urgency, and urge incontinence: evidence from functional brain imaging. Neurourol Urodyn 2008;27:466-74. PMID: 18092336
crossref pmid
15. Craig AD. How do you feel? Interoception: the sense of the physiological condition of the body. Nat Rev Neurosci 2002;3:655-66. PMID: 12154366
crossref pmid pdf
16. Kim JW, Kim SJ, Park JM, Na YG, Kim KH. Past, present, and future in the study of neural control of the lower urinary tract. Int Neurourol J 2020;24:191-9. PMID: 33017890
crossref pmid pdf
17. Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 2006;175:191-4 discussion 194-5. PMID: 16406907
crossref pmid
18. Griffiths D, Derbyshire S, Stenger A, Resnick N. Brain control of normal and overactive bladder. J Urol 2005;174:1862-7. PMID: 16217325
crossref pmid
19. Tadic SD, Griffiths D, Schaefer W, Cheng CI, Resnick NM. Brain activity measured by functional magnetic resonance imaging is related to patient reported urgency urinary incontinence severity. J Urol 2010;183:221-8. PMID: 19913803
crossref pmid pmc
20. Griffiths DJ, Tadic SD, Schaefer W, Resnick NM. Cerebral control of the lower urinary tract: how age-related changes might predispose to urge incontinence. Neuroimage 2009;47:981-6. PMID: 19427909
crossref pmid pmc
21. Ketai LH, Komesu YM, Dodd AB, Rogers RG, Ling JM, Mayer AR. Urgency urinary incontinence and the interoceptive network: a functional magnetic resonance imaging study. Am J Obstet Gynecol 2016;215:449.e1-449.e17. PMID: 27173081
crossref pmid pmc
22. Cho WY, Kim SC, Kim SO, Park S, Lee SD, Chung JM, et al. Can recording only the day-time voided volumes predict bladder capacity? Investig Clin Urol 2018;59:194-9. PMID: 29744477
crossref pmid pmc pdf
23. Rittig S, Kamperis K, Siggaard C, Hagstroem S, Djurhuus JC. Age related nocturnal urine volume and maximum voided volume in healthy children: reappraisal of International Children’s Continence Society definitions. J Urol 2010;183:1561-7. PMID: 20176383
crossref pmid
24. Mattsson S, Gladh G, Lindström S. Relative filling of the bladder at daytime voids in healthy school children. J Urol 2003;170:1343-6. PMID: 14501766
crossref pmid
25. Coenen A. Sensory gating and gaining in sleep: the balance between the protection of sleep and the safeness of life (a review). J Sleep Res 2024;33:e14152. PMID: 38286435
crossref pmid
26. McCormick DA, Bal T. Sensory gating mechanisms of the thalamus. Curr Opin Neurobiol 1994;4:550-6. PMID: 7812144
crossref pmid
27. Gent TC, Bandarabadi M, Herrera CG, Adamantidis AR. Thalamic dual control of sleep and wakefulness. Nat Neurosci 2018;21:974-84. PMID: 29892048
crossref pmid pmc pdf
28. Lewis LD, Voigts J, Flores FJ, Schmitt LI, Wilson MA, Halassa MM, et al. Thalamic reticular nucleus induces fast and local modulation of arousal state. Elife 2015;4:e08760. PMID: 26460547
crossref pmid pmc pdf
29. Jang HJ, Kwon MJ, Cho KO. Central regulation of micturition and its association with epilepsy. Int Neurourol J 2018;22:2-8. PMID: 29609418
crossref pmid pmc pdf
30. Negoro H, Kanematsu A, Doi M, Suadicani SO, Matsuo M, Imamura M, et al. Involvement of urinary bladder Connexin43 and the circadian clock in coordination of diurnal micturition rhythm. Nat Commun 2012;3:809. PMID: 22549838
pmid pmc
31. Ohayon MM, Carskadon MA, Guilleminault C, Vitiello MV. Metaanalysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan. Sleep 2004;27:1255-73. PMID: 15586779
crossref pmid
32. Margel D, Shochat T, Getzler O, Livne PM, Pillar G. Continuous positive airway pressure reduces nocturia in patients with obstructive sleep apnea. Urology 2006;67:974-7. PMID: 16635510
crossref pmid
33. Rackley R, Weiss JP, Rovner ES, Wang JT, Guan Z; 037 STUDY GROUP. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 2006;67:731-6 discussion 736. PMID: 16618562
crossref pmid
34. Andersson KE. Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol 2011;59:377-86. PMID: 21168951
crossref pmid
35. Aizawa N, Homma Y, Igawa Y. Effects of mirabegron, a novel β3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin. Eur Urol 2012;62:1165-73. PMID: 22981677
crossref pmid
36. Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, MacDiarmid SA. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. J Urol 2013;189:2194-201. PMID: 23219541
crossref pmid
37. Weissbart SJ, Bhavsar R, Rao H, Wein AJ, Detre JA, Arya LA, et al. Specific changes in brain activity during urgency in women with overactive bladder after successful sacral neuromodulation: a functional magnetic resonance imaging study. J Urol 2018;200:382-8. PMID: 29630979
crossref pmid
38. Gill BC, Pizarro-Berdichevsky J, Bhattacharyya PK, Brink TS, Marks BK, Quirouet A, et al. Real-time changes in brain activity during sacral neuromodulation for overactive bladder. J Urol 2017;198:1379-85. PMID: 28645869
crossref pmid
39. Felde G, Ebbesen MH, Hunskaar S. Anxiety and depression associated with urinary incontinence. A 10-year follow-up study from the Norwegian HUNT study (EPINCONT). Neurourol Urodyn 2017;36:322-8. PMID: 26584597
crossref pmid pdf
40. Mehr AA, Kreder KJ, Lutgendorf SK, Ten Eyck P, Greimann ES, Bradley CS. Daily symptom associations for urinary urgency and anxiety, depression and stress in women with overactive bladder. Int Urogynecol J 2022;33:841-50. PMID: 34842938
crossref pmid pdf
41. Okamoto T, Hatakeyama S, Imai A, Yamamoto H, Yoneyama T, Mori K, et al. The association between serum serotonin levels and overactive bladder: results from a community-based cross-sectional study in Japan. World J Urol 2021;39:169-75. PMID: 32193653
crossref pmid pdf
42. de Groat WC. Influence of central serotonergic mechanisms on lower urinary tract function. Urology 2002;59:30-6. PMID: 12007520
crossref pmid
43. Mills KA, West EG, Sellers DJ, Chess-Williams R, McDermott C. Psychological stress induced bladder overactivity in female mice is associated with enhanced afferent nerve activity. Sci Rep 2021;11:17508. PMID: 34471159
crossref pmid pmc pdf
44. Reynolds WS, McKernan LC, Dmochowski RR, Bruehl S. The biopsychosocial impacts of anxiety on overactive bladder in women. Neurourol Urodyn 2023;42:778-84. PMID: 36780135
crossref pmid pdf
45. Sinha S. Dysfunctional voiding: a review of the terminology, presentation, evaluation and management in children and adults. Indian J Urol 2011;27:437-47. PMID: 22279306
crossref pmid pmc
46. Clothier JC, Wright AJ. Dysfunctional voiding: the importance of non-invasive urodynamics in diagnosis and treatment. Pediatr Nephrol 2018;33:381-94. PMID: 28567611
crossref pmid pdf
47. Groutz A, Blaivas JG, Chaikin DC. Bladder outlet obstruction in women: definition and characteristics. Neurourol Urodyn 2000;19:213-20. PMID: 10797578
crossref pmid
TOOLS
Share :
Facebook Twitter Linked In Google+
METRICS Graph View
  • 0 Crossref
  • 0 Scopus
  • 1,109 View
  • 48 Download
We recommend


ARTICLE & ORGAN
Article Category

Browse all articles >

Organ

Browse all articles >

ISSUES
DISEASES & TOPICS
Diseases

Browse all articles >

Topics

Browse all articles >

AUTHOR
INFORMATION

Official Journal of Korean Society of Functional and Reconstructive Urology & ESSIC (International Society for the Study of BPS) & Korean Society of Urological Research & The Korean Children’s Continence and Enuresis Society & The Korean Association of Urogenital Tract Infection and Inflammation & Korean Society of Geriatric Urological Care
Editorial Office
Department of Urology, Kangbuk Samsung Medical Center, Sungkyunkwan University School of Medicine,
29 Saemunan-ro, Jongno-gu, Seoul 03181, Korea
Tel: +82-2-2001-2237     Fax: +82-2-2001-2247    E-mail: support@einj.org

Copyright © 2026 by Korean Society of Functional and Reconstructive Urology.

Developed in M2PI

Close layer
prev next